Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
11/06/2026 15:48
BRIEF-PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients June 11 (Reuters) - PeptiDream Inc 4587.T:
PEPTIDREAM ANNOUNCES FIRST DOSING OF CLAUDIN18.2 TARGETING RADIOPHARMACEUTICAL CANDIDATE 64CU-PD-29875 IN PATIENTS WITH GASTRIC CANCER
Source text: ID:nBwbFs9l2a
Further company coverage: 4587.T
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner